Ozempic in liver disease — no dose adjustment needed in hepatic impairment per the label, plus the fatty-liver/MASH benefit evidence (semaglutide's hepatic effects).
Short answer: The FDA label says no dose adjustment is needed for hepatic impairment — semaglutide is metabolized differently (proteolysis, not liver enzymes). Bonus: semaglutide shows benefit in fatty liver disease (MASH), reducing liver fat and inflammation in trials.
Safety in liver impairment
Unlike most drugs, semaglutide doesn't rely on liver metabolism — it's broken down proteolytically. The label: no dose adjustment in hepatic impairment. Severe liver disease still warrants doctor oversight.
The fatty-liver upside
Semaglutide actually improves MASLD/MASH (fatty liver) — trials show reduced liver fat, ALT improvement, and MASH resolution rates vs placebo. For diabetics with fatty liver (extremely common overlap), this is a genuine secondary benefit.
No dose adjustment needed per the label — it's not metabolized by liver enzymes. Severe disease still warrants monitoring.
Yes — trials show MASH resolution and liver-fat reduction. It's one of semaglutide's emerging benefits.
FDA label; semaglutide MASH trials (Lancet/NEJM).